Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as $11.16 and last traded at $10.92, with a volume of 336528 shares changing hands. The stock had previously closed at $10.98.
Analyst Ratings Changes
Separately, Canaccord Genuity Group assumed coverage on Niagen Bioscience in a research note on Tuesday. They issued a "buy" rating and a $13.00 price objective on the stock.
View Our Latest Research Report on Niagen Bioscience
Niagen Bioscience Trading Down 0.1%
The stock has a market capitalization of $851.50 million, a price-to-earnings ratio of 63.59 and a beta of 1.94. The stock's 50-day moving average is $8.13.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Featured Articles
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
